Lhasa Limited
Lhasa Limited is a UK-registered charity (founded 1983) that develops in silico software for chemical safety assessment, serving pharmaceutical, cosmetics, agrochemical, and medical device manufacturers via a membership-based licensing model anchored by curated toxicity databases and pre-competitive data sharing consortiums.
- Company typePrivate
- Founded1983
- HeadquartersLeeds, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What Lhasa Limited does
Lhasa Limited is a UK-registered charity (no. 290866) founded in 1983 and headquartered in Leeds, operating as a not-for-profit membership organisation that develops in silico software for chemical safety assessment. The company serves pharmaceutical, cosmetics, agrochemical, and medical device manufacturers, with top-20 pharmaceutical companies participating as both members and data contributors to its consortium-based knowledge base. Its technology portfolio comprises nine integrated products — Derek Nexus, Sarah Nexus, Vitic, Meteor, Kaptis, Acrostic, Mirabilis, Zeneth, and LCDB Plus — covering mutagenicity, carcinogenicity, metabolism, impurity, and skin sensitisation assessment, all aligned with major regulatory frameworks (ICH M7, ICH Q3A/B, ICH Q3E, REACH, ISO 10993).
The company's underlying technology combines knowledge-based expert systems, statistical (Q)SAR models, and curated toxicity databases containing over 30,000 peer-reviewed records across 22,000+ substances. Pre-competitive data sharing consortiums (aromatic amines, elemental impurities, complex nitrosamines, excipients, intermediates, organosilicons) enable members to contribute and access proprietary experimental data, creating a collaborative data flywheel. Distribution is direct enterprise sales via annual membership licensing, supplemented by training, technical support, and a scientific marketing program spanning publications, webinars, symposia, and regulatory engagement.
Revenue mechanics are membership-based annual licensing with quote-based pricing (not publicly disclosed). The company reinvests proceeds into software development and collaborative research rather than distributing profit, consistent with its charitable mission. Recent inorganic activity includes the January 2025 acquisitions of Molecular Networks GmbH and Altamira, both undisclosed, signalling expansion of computational chemistry and molecular modelling capabilities beyond the legacy toxicology core.
Lhasa Limited firmographics
Firmographics- Name
- Lhasa Limited
- Legal name
- Lhasa Limited
- Website
- https://lhasalimited.org
- Company type
- Private
- Founded year
- 1983
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Lhasa Limited is a UK-registered charity (founded 1983) that develops in silico software for chemical safety assessment, serving pharmaceutical, cosmetics, agrochemical, and medical device manufacturers via a membership-based licensing model anchored by curated toxicity databases and pre-competitive data sharing consortiums.
- Ownership category
- akta.pro rank
Where Lhasa Limited is headquartered
LocationHeadquarters
- HQ city
- Leeds
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Lhasa Limited business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Membership-based Software Licensing: Lhasa operates as a not-for-profit membership organisation offering annual software licensing agreements. Members gain access to in silico solutions, curated toxicity databases, and participation in pre-competitive data sharing initiatives. Solution benefits are accessible to members through separate licensing of Lhasa Limited solutions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Annual membership licensing |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels9 records
Lhasa Limited product offering
Product offeringCore offering
Lhasa Limited develops and licenses in silico scientific software for chemical safety decision-making, including knowledge-based (Q)SAR prediction tools (Derek Nexus, Sarah Nexus), curated toxicity databases (Vitic, LCDB Plus), metabolism prediction software (Meteor), guided carcinogenicity decision support (Kaptis), and read-across platforms for nitrosamine and extractables/leachables risk assessment (Acrostic, Mirabilis, Zeneth). Its solutions are licensed to pharmaceutical, cosmetics, agrochemical, and medical device companies to support regulatory submissions under ICH M7, ICH Q3A/B, ICH Q3E, REACH, and ISO 10993 frameworks.
Product overview
Lhasa Limited provides a suite of in silico scientific software solutions for chemical safety assessment, organized around two main pillars: (1) Software Solutions including Derek Nexus and Sarah Nexus for in silico mutagenicity assessment, Vitic as a toxicity database, Meteor for metabolism prediction, Kaptis for carcinogenicity assessment, Acrostic for read-across, and Zeneth and Mirabilis for nitrosamine risk assessment; and (2) Data Sharing initiatives enabling precompetitive data exchange across pharmaceutical, chemical, and consumer product industries. The products are delivered as both desktop software and cloud-based membership access, with solutions addressing regulatory compliance requirements including ICH M7, ICH Q3A/B, REACH, and emerging ICH Q3E guidelines.
Differentiator
Problem solved
Functional benefit
Brands
- Derek Nexus: Expert knowledge-based software for in silico mutagenicity assessment using (Q)SAR predictions.
- Sarah Nexus
- Kaptis
- Vitic
- Meteor
- Acrostic
- Mirabilis
- Zeneth
- LCDB Plus
Products and services
- Derek Nexus Expert knowledge-based (Q)SAR software for predicting mutagenicity of chemical compounds, providing clear mechanistic rationales and literature-derived evidence for every prediction, used by pharmaceutical and chemical safety scientists to support ICH M7 regulatory submissions.
- Sarah Nexus Statistical machine learning (Q)SAR prediction tool for mutagenicity assessment, providing complementary predictions to Derek Nexus for comprehensive in silico mutagenicity evaluation and ICH M7 submissions.
- Vitic Expert-curated chemical toxicity database offering structure-based searches and rapid access to over 30,000 peer-reviewed toxicity records spanning carcinogenicity, genotoxicity, and skin sensitisation endpoints across 22,000+ substances.
- Meteor Knowledge-based expert system for metabolism prediction and metabolite identification (MetID), providing mechanistic rationales and literature-derived evidence for biotransformation predictions, supporting ICH M7, ICH M3 (MIST), ICH Q3A&B and REACH guidelines.
- Kaptis Guided decision support software for carcinogenicity assessment, providing structured question-based workflows with confidence scoring and transparent scientific rationales to support defensible safety decisions.
- Acrostic In silico read-across solution for nitrosamine impurity and extractables and leachables (E&L) risk assessment, providing curated datasets, structured workflows, and expert-led scientific logic to support defensible safety decisions with up to 90% time savings.
- Zeneth Software solution for nitrosamine impurity risk assessment in pharmaceutical development, supporting safety profiling workflows for impurities and degradants.
- Mirabilis In silico tool for monitoring and predicting the risk of nitrosamine impurity formation and assessing toxicological concern in pharmaceutical products.
- LCDB Plus Specialised Lhasa Carcinogenicity Database providing curated carcinogenicity data for chemical safety risk assessment decision-making, used as a knowledge source for carcinogenicity workflows.
Quantifiable outcome
- Acrostic read-across tool demonstrates up to 90% time savings compared to fully manual read-across workflows
- +4 more outcomes
Companies that use Lhasa Limited
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles4 records
Lhasa Limited technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature9 records
Lhasa Limited partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core.
- AstraZenecacoreContributed expertise to Lhasa's collaborative whitepaper on implementing the UK Government strategy for replacing animals in science. Participated in a cross-sector roundtable convened by Lhasa addressing NAMs adoption in safety assessment.
- GlaxoSmithKlinecoreContributed executive perspective (Dr Anthony Lynch, Executive Director of Genetic and Investigative Toxicology) to Lhasa's UK NAMs strategy whitepaper roundtable, providing industry insights on NAMs adoption.
- Cruelty Free InternationalcoreContributed senior perspective (Dr Charlie Stevenson, Senior Chemicals Regulatory Advisor) to Lhasa's collaborative whitepaper on replacing animals in science, representing the animal welfare NGO perspective on NAMs.
- UnilevercoreParticipated in Lhasa's cross-sector roundtable contributing expertise on consumer product safety and NAMs adoption across chemical safety assessment.
- NC3Rs (National Centre for the Replacement, Refinement & Reduction of Animals in Research)coreContributed to Lhasa's UK NAMs strategy whitepaper roundtable, providing research funding and 3Rs expertise perspective on replacing animals in science.
- LabcorpcoreParticipated in Lhasa's cross-sector roundtable bringing contract research organisation (CRO) perspective on NAMs implementation in safety assessment.
- SyngentacoreContributed to Lhasa's UK NAMs strategy whitepaper roundtable representing agrochemical industry perspective on non-animal approach adoption.
- Liverpool John Moores UniversitycoreParticipated in Lhasa's cross-sector roundtable providing academic research perspective on NAMs validation and qualification.
- Kirkland ConsultingcoreContributed genetic toxicology consulting expertise to Lhasa's roundtable on implementing UK NAMs strategy.
- Global Regulatory Bodies (EPA, FDA, EMA)coreLhasa solutions are aligned with regulatory guidance from EPA, FDA, EMA, and other international regulatory bodies. Regulatory pressures from these bodies are identified as key drivers in the computational toxicology market. Vitic data is accessed by regulatory bodies for validation purposes.
- Data Sharing Consortium MemberscoreLhasa facilitates pre-competitive data sharing consortiums including aromatic amines, elemental impurities (ICH Q3D), complex nitrosamines, nitrite impurities, excipients, and FDA RCA initiatives. Consortium members contribute and access high-quality experimental data.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Lhasa Limited competitors and assessment
Company assessmentDirect peers
- MultiCASE (CASE): MultiCASE is a long-standing direct competitor providing knowledge-based (Q)SAR expert systems (CASE Ultra, META Ultra) for mutagenicity, carcinogenicity, and other toxicology endpoints — the closest analogue to Derek Nexus in approach and customer base.
- Simulations Plus: Simulations Plus offers ADMET predictor software and Tox/Sim solutions that compete directly with Lhasa's Derek Nexus, Sarah Nexus, and Meteor for in silico ADMET and metabolite prediction across pharma and chemical safety customers.
- Instem (Leadscope): Instem acquired Leadscope, which provides in silico toxicology software (Leadscope Model Applier, Genetox) directly competing with Derek Nexus and Sarah Nexus. Both serve pharma and chemical safety assessment with (Q)SAR and expert-rule-based prediction systems.
Broad incumbents
- Inotiv: Inotiv is a preclinical CRO with computational toxicology and study management software. It competes with Lhasa in parts of the chemical safety assessment workflow while serving a much broader drug development customer base.
- Schrödinger: Schrödinger is a broader computational chemistry and materials platform that includes toxicity and ADMET prediction capabilities. It is a much larger, publicly traded incumbent that overlaps with Lhasa's pharma safety assessment use cases as part of a wider portfolio.
- Biovia (Dassault Systèmes): BIOVIA from Dassault Systèmes is a broad scientific software platform that includes molecular modelling, registration, and safety assessment tools used by large pharma. It is an incumbent competitor in adjacent parts of Lhasa's chemical safety workflow.
Others
- ChemAxon: ChemAxon provides cheminformatics toolkits and software components used widely in drug discovery and chemical safety workflows. It is adjacent infrastructure that overlaps with parts of Lhasa's portfolio following the Molecular Networks acquisition.
Emerging players
- MolPort (cheminformatics): MolPort provides chemical sourcing and cheminformatics infrastructure used in compound safety evaluation workflows. It overlaps with parts of Lhasa's portfolio following the Molecular Networks and Altamira acquisitions.
- Deciphex (Patholytix): Deciphex's Patholytix division applies digital pathology and AI to toxicology and drug safety. It overlaps with Lhasa's safety assessment focus but addresses histopathology rather than in silico (Q)SAR prediction.
- Scitovation: Scitovation is a non-profit scientific organisation focused on advancing computational toxicology and NAMs. It is structurally comparable to Lhasa as a mission-driven non-profit working in the same in silico safety assessment space.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Lhasa Limited social profiles
Digital presenceLhasa Limited financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lhasa Limited leadership team
Management profileNumber of profiles
Profiles4 records
Lhasa Limited funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lhasa Limited M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lhasa Limited
What does Lhasa Limited do?
Lhasa Limited develops and licenses in silico scientific software for chemical safety decision-making, including knowledge-based (Q)SAR prediction tools (Derek Nexus, Sarah Nexus), curated toxicity databases (Vitic, LCDB Plus), metabolism prediction software (Meteor), guided carcinogenicity decision support (Kaptis), and read-across platforms for nitrosamine and extractables/leachables risk assessment (Acrostic, Mirabilis, Zeneth). Its solutions are licensed to pharmaceutical, cosmetics, agrochemical, and medical device companies to support regulatory submissions under ICH M7, ICH Q3A/B, ICH Q3E, REACH, and ISO 10993 frameworks.
Is Lhasa Limited a public or private company?
Lhasa Limited is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Lhasa Limited founded?
Lhasa Limited was founded in 1983. It employs 51 to 100 people.
Where is Lhasa Limited based?
Lhasa Limited is headquartered in Leeds, United Kingdom, in the Europe region.
How does Lhasa Limited make money?
One revenue line is on record: membership-based Software Licensing.
Who are Lhasa Limited's main competitors?
Direct peers on record are MultiCASE (CASE), Simulations Plus and Instem (Leadscope). Broad incumbents are Inotiv, Schrödinger and Biovia (Dassault Systèmes). ChemAxon is listed as an others. Emerging players are MolPort (cheminformatics), Deciphex (Patholytix) and Scitovation.
Does Lhasa Limited have an API?
No public API is recorded for Lhasa Limited.